KIND Pharmaceutical Reports Preclinical Results of AND017 in Animal Models of Multiple Disorders
Shots:
- Kind highlighted the preclinical data of AND017 in Townes SCD, inducible Mutant c-Myc Knock-in MDS & Hbbd3th β-thalassemia mouse models at ASH 2024
- Results showed elevated hemoglobin (Hb), RBC, hematocrit (HCT) & reduced mitochondrial retention in reticulocytes & mature RBCs in Townes SCD model; enhanced Hb, RBC & HCT plus less efficacy with high-dose epoetin (EPO) in MDS model; increased Hb by 22%, RBC by 14%, HCT by 21% & improved RBC morphology with 15 mg/kg in β-thalassemia model
- Furthermore, the US FDA has approved IND application of AND017 for SCD, following its ODD in SCD and successful P-II trials for anemia in NDD-CKD and DD-CKD across the US & China
Ref: KIND Pharmaceutical | Image: KIND Pharmaceutical
Related News:- Kind Pharmaceutical’s AND017 Gains the US FDA’s Orphan Drug Designation to Treat SCD
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
